Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17α activity and serum androgens

Journal of Clinical Endocrinology and Metabolism

Volumn 82, Issue 12, 1997, Pages 4075-4079

  Nestler, John E ^a,c   Jakubowicz, Daniela J ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b Hospital de Clinicas Caracas   (Venezuela)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; HYDROXYPROGESTERONE; INSULIN; METFORMIN;

ADULT; ANDROGEN SYNTHESIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL;

EID: 0030783316     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.82.12.4431     Document Type: Article

References (42)

1. Franks S. 1995 Polycystic ovary syndrome. N Engl J Med. 333:853-861.
2. Chang RJ, Nakamura RM, Judd HL, Kaplan SA. 1983 Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 57:356-359.
3. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 38:1165-1174.
4. Dunaif A, Green G, Futterweit W, Dobrjansky A. 1990 Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab. 70:699-704.
5. Carmina E, Koyama T, Chang L, Stanczyk FZ, Lobo RA. 1992 Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol. 167:1807-1812.
6. Ciaraldi TP, el Roeiy A, Madar Z, Reichart D, Olefsky JM, Yen SSC. 1992 Cellular mechanisms of insulin resistance in polycystic ovarian syndrome. J Clin Endocrinol Metab. 75:577-583.
7. Dunaif A, Xia J, Book CB, Schenker E, Tang Z. 1995 Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 96:801-810.
8. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS. 1995 Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 96:520-527.
9. Apter D, Butzow T, Laughlin GA, Yen SS. 1995 Metabolic features of polycystic ovary syndrome are found in adolescent girls with hyperandrogenism. J Clin Endocrinol Metab. 80:2966-2973.
10. Nestler JE. 1994 Role of obesity and insulin in the development of anovulation. In: Filicori M, Flamigni C, eds. Ovulation induction: basic science and clinical advances. Amsterdam: Elsevier; 103-114.
11. Barbieri RL, Makris A, Randall RW, Daniels G, Kristner RW, Ryan KJ. 1986 Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J Clin Endocrinol Metab. 62:904-910.
12. Cara JF, Rosenfield RL. 1988 Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells. Endocrinology. 123:733-739.
13. Bergh C, Carlsson B, Olsson JH, Selleskog U, Hillensjo T. 1993 Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin. Fertil Steril. 59:323-331.
14. Nahum R, Thong KJ, Hillier SG. 1995 Metabolic regulation of androgen production by human thecal cells in vitro. Hum Reprod. 10:75-81.
15. Nestler JE, Barlascini CO, Matt DW, et al. 1989 Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 68:1027-1032.
16. Nestler JE, Jakubowicz DJ. 1996 Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction in insulin secretion in women with polycystic ovary syndrome. N Engl J Med. 335:617-623.
17. Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. 1996 The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab. 81:3299-3306.
18. Jakubowicz DJ, Nestler JE. 1997 17α-Hydroxyprogesterone response to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J Clin Endocrinol Metab. 82:556-560.
19. Plymate SR, Matej LA, Jones RE, Friedl KE. 1988 Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J Clin Endocrinol Metab. 67:460-464.
20. Nestler JE, Powers LP, Matt DW, et al. 1991 A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab. 72:83-89.
21. Ehrmann DA, Rosenfield RL, Barnes RB, Brigell DF, Sheikh Z. 1992 Detection of functional ovarian hyperandrogenism in women with androgen excess. N Engl J Med. 327:157-162.
22. Rosenfield RL, Barnes RB, Ehrmann DA. 1994 Studies of the nature of 17- hydroxyprogesterone hyperresonsiveness to gonadotropin-releasing hormone agonist challenge in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 79:1686-1692.
23. White D, Leigh A, Wilson C, Donaldson A, Franks S. 1995 Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 42:475-181.
24. Grulet H, Hecart AC, Delemer B, et al. 1993 Roles of LH and insulin resistance in lean and obese polycystic ovary syndrome. Clin Endocrinol (Oxf). 38:621-626.
25. Holte J, Bergh T, Gennarelli G, Wide L. 1994 The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol (Oxf). 41:473-481.
26. Dale PO, Tanbo T, Vaaler S, Abyholm T. 1992 Body weight, hyperinsulinemia, and gonadotropin levels in the polycystic ovarian syndrome: evidence of two distinct populations. Fertil Steril. 58:487-491.
27. Jacobs HS. 1995 Polycystic ovary syndrome: aetiology and management. Curr Opin Obstet Gynecol. 7:203-208.
28. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. 1987 Characterization of groups of hyperandrogenemic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab. 65:499-507.
29. Morales AJ, Laughlin GA, Butzow T, et al. 1996 Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J Clin Endocrinol Metab. 81:2854-2864.
30. Barnes RB, Rosenfield RL. 1989 Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N Engl J Med. 320:559-565.
31. Nagi DK, Yudkin JS. 1993 Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care. 16:621-629.
32. DeFronzo RA, Barzilai N, Simonson DC. 1991 Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects. J Clin Endocrinol Metab. 73:1294-1301.
33. Yeh HC, Futterweit W, Thornton JC. 1987 Polycystic ovarian disease: US features in 104 patients. Radiology. 163:111-116.
34. Prelevic GM, Wurzburger MI, Balint-Peric L. 1990 LH pulsatility and response to a single s.c. injection of buserelin in polycystic ovary syndrome. Gynecol Endocrinol. 4:1-13.
35. Adashi EY, Hsueh AJW, Yen SSC. 1981 Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology. 108:1441-1449.
36. Yen SS, Laughlin GA, Morales AJ. 1993 Interface between extra- and intraovarian factors in polycystic ovarian syndrome. Ann NY Acad Sci. 687:98-111.
37. Nestler JE, Jakubowicz DJ, Falcon de Vargas A, Brik C, Quintero N, Medina F. In the polycystic ovary syndrome insulin stimulates human thecal testosterone production via its own receptor by using inositolglycan mediators as the signal transduction system [Abstract P2-418]. Proc of the 79th Annual Meet of The Endocrine Soc. 1997; 389.
38. Moghetti P, Castello R, Negri C, et al. 1996 Insulin infusion amplifies 17α-hydroxycorticoid intermediates response to adrenocorticotropin in hyperandrogenic women: apparent impairment of 17,20-lyase activity. J Clin Endocrinol Metab. 81:881-886.
39. Garzo VG, Dorrington JH. 1984 Aromatase activity in human granulosa cells during follicular development and the modulation of follicle-stimulating hormone and insulin. Am J Obstet Gynecol. 148:657-662.
40. Erickson GF, Magoffin DA, Cragun JR, Chang RJ. 1990 The effects of insulin and insulin-like growth factors-I and -II on estradiol production by granulosa cells of polycystic ovaries. J Clin Endocrinol Metab. 70:894-902.
41. Rebuffe-Scrive M, Cullberg G, Lundberg P, Lindstedt G, Björntorp P. 1989 Anthropometric variables and metabolism in polycystic ovarian disease. Horm Metab Res. 21:391-397.
42. Bringer J, Lefebvre P, Boulet F, et al. 1993 Body composition and regional fat distribution in polycystic ovarian syndrome. Relationship to hormonal and metabolic profiles. Ann NY Acad Sci. 687:115-123.